Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

References

• Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561–1572.Availble from: https://www.fujita-hu.ac.jp/~psychi/html/kenkyunaiyoyakuri.html. Accessed May 07, 2019. 26388529
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007;64(5):543–552. doi:10.1001/archpsyc.64.5.54317485606
   PubMed Web of Science ®Google Scholar
• Kendall T, Morriss R, Mayo-Wilson E, Marcus E. Guideline development group of the national institute for H, care E. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014;349:g5673.25258392
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.23480132
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.29536616
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Yatham L, Grunze H, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm. Int J Neuropsychopharmacol. 2017;20(2):121–179.27816941
   PubMed Web of Science ®Google Scholar
• Fornaro M, De Berardis D, Koshy AS, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat. 2016;12:719–735. doi:10.2147/NDT.S10084627099503
   PubMed Web of Science ®Google Scholar
• Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI, Bipolar I. a five-year prospective follow-up. J Nerv Ment Dis. 1993;181(4):238–245.8097229
   PubMed Web of Science ®Google Scholar
• Bradley AJ, Webb-Mitchell R, Hazu A, et al. Sleep and circadian rhythm disturbance in bipolar disorder. Psychol Med. 2017;47(9):1678–1689. doi:10.1017/S003329171700018628173893
   PubMed Web of Science ®Google Scholar
• Jones SH, Hare DJ, Evershed K. Actigraphic assessment of circadian activity and sleep patterns in bipolar disorder. Bipolar Disord. 2005;7(2):176–186.15762859
   PubMed Web of Science ®Google Scholar
• Takaesu Y. Circadian rhythm in bipolar disorder: A review of the literature. Psychiatry Clin Neurosci. 2018;72(9):673–682.29869403
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Kutcher SP, Ralevski E, Brown GM. Nocturnal melatonin and 24 hr 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res. 1996;63(2–3):219–222. doi:10.1016/0165-1781(96)02910-18878318
   PubMed Web of Science ®Google Scholar
• Rozerem FDA (Ramelteon) tablets drug approval package; 2005; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_RozeremTOC.cfm. Accessed January 6, 2019.
   Google Scholar
• Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003;8:d1093–1108.12957828
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Calabrese JR, Macek TA, et al. Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. J Affect Disord. 2017;221:275–282. doi:10.1016/j.jad.2017.06.04428662460
   PubMed Web of Science ®Google Scholar
• McElroy SL, Winstanley EL, Martens B, et al. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol. 2011;26(1):48–53. doi:10.1097/YIC.0b013e3283400d3520861739
   PubMed Web of Science ®Google Scholar
• Norris ER, Karen B, Correll JR, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord. 2013;144(1–2):141–147. doi:10.1016/j.jad.2012.06.02322963894
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326.8290681
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 The Cochrane Collaboration; 2011 Available from: www.cochrane-handbook.org. Accessed January 6, 2019.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b265119622551
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.728692
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.444788
   PubMed Web of Science ®Google Scholar
• Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 1986;18(1):65–87. doi:10.1016/0165-1781(86)90060-03737788
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi:10.1016/0165-1781(89)90047-42748771
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.3802833
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.55712958120
   PubMed Web of Science ®Google Scholar
• Wang HR, Woo YS, Bahk WM. The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review. Int Clin Psychopharmacol. 2016;31(6):301–306. doi:10.1097/YIC.000000000000013527294772
   PubMed Web of Science ®Google Scholar
• De Crescenzo F, Lennox A, Gibson JC, et al. Melatonin as a treatment for mood disorders: a systematic review. Acta Psychiatr Scand. 2017;136(6):549–558. doi:10.1111/acps.1275528612993
   PubMed Web of Science ®Google Scholar
• Igwe SC, Brigo F. Does melatonin and melatonin agonists improve the metabolic side effects of atypical antipsychotics?: A systematic review and meta-analysis of randomized controlled trials. Clin Psychopharmacol Neurosci. 2018;16(3):235–245. doi:10.9758/cpn.2018.16.3.23530121990
   PubMed Web of Science ®Google Scholar
• Mostafavi SA, Solhi M, Mohammadi MR, Akhondzadeh S. Melatonin for reducing weight gain following administration of atypical antipsychotic olanzapine for adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2017;27(5):440–444. doi:10.1089/cap.2016.004628339282
   PubMed Web of Science ®Google Scholar
• Mostafavi A, Solhi M, Mohammadi MR, Hamedi M, Keshavarzi M, Akhondzadeh S. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Med Iran. 2014;52(10):734–739.25369006
   PubMedGoogle Scholar
• Leibenluft E, Feldman-Naim S, Turner EH, Wehr TA, Rosenthal NE. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J Clin Psychiatry. 1997;58(9):383–388.9378688
   PubMed Web of Science ®Google Scholar